Investigations into, and development of, a lyophilized and formulated recombinant human factor IX produced from CHO cells
To develop a recombinant human factor IX (rFIX) formulation equivalent to commercially available products in terms of cake appearance, residual moisture, proportion of soluble aggregates and activity maintenance for 3 months at 4–8 °C.
NaCl and low bulking agent/cryoprotectant mass ratio had a negative impact on cake quality upon lyophilisation for a wide range of formulations tested. Particular devised formulations maintained rFIX activity after lyophilization with a similar performance when compared with the rFIX formulated using the excipients reported for a commercially available FIX formulation (Benefix). rFIX remained active after 3 months when stored at 4 °C, though this was not the case with samples stored at 40 °C. Interestingly, particular formulations had an increase in residual moisture after 3 months storage, but not above a 3% threshold. All four formulations tested were equivalent to the Benefix formulation in terms of particle size distribution and cake appearance.
Three specific formulations, consisting of surfactant polysorbate-80, sucrose or trehalose as cryoprotectant, mannitol or glycine as bulking agent, l-histidine as buffering agent, and NaCl added in the reconstitution liquid at 0.234% (w/v) were suitable for use with a CHO cell-derived recombinant FIX.
KeywordsExcipients Formulation Freeze-drying Lyophilization Recombinant factor IX Stability study
- Baxalta Canada Corporation (2015) Product Monograph Rixubis Recombinant Coagulation Factor IX (rFIX), Nonacog gamma. http://www.baxalta.ca/downloads/Product_Monographs/en/Rixubis.pdf. Accessed 4 November 2016
- EMEA (2005) Scientific Discussion.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000139/WC500020386.pdf. Accessed 12 March 2017
- Passot S, Tréléa IC, Marin M, Fonseca F (2010) The relevance of thermal properties for improving formulation and cycle development: application to freeze-drying of proteins. In: Rey L, May JC (eds) Freeze drying/lyophilization of pharmaceutical and biological products, 3rd edn. Inf Healthc, New York, pp 136–166Google Scholar
- Pfizer (2012) Product Monograph Benefix Coagulation Factor IX (recombinant). http://www.pfizer.ca/sites/g/files/g10017036/f/201410/BENEFIX_PM_E_153056_27Dec2012.pdf. Accessed 4 November 2016
- Ribeiro DA (2013) Processo de purificação de fator IX recombinante produzido em células da linhagem CHO. Ph.D. thesis, Federal University of Rio de Janeiro (Brazil)Google Scholar
- Webb C, Bush L, Schaub RG (1997) Highly concentrated, lyophilized, and liquid factor IX formulations. Patent WO 1997026909:A1Google Scholar